Gryphon Financial Partners’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Gryphon Financial Partners’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-217	Closed	-$12K	–	640
2018 Q2	$12K	Hold	217	–	–	0.01%	478
2018 Q1	$11K	Buy	217 +59	+37%	+$3.01K	0.01%	506
2017 Q4	$7K	Buy	+158	New	+$7.41K	﹤0.01%	662

Other funds holding PBE

ACM

Arlington Capital Management Arlington Heights, Illinois $161M AUM 38.38% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return

Gryphon Financial Partners's PBE Position: Q3 2018 in Review

Gryphon Financial Partners sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2018, closing a stake of 217 shares — an estimated $12K sold.

Gryphon Financial Partners first reported a position in PBE in Q4 2017 and held it in 3 quarters. The position peaked at $12K in Q2 2018. 74 funds tracked by Wall St. Rank hold PBE as of Q3 2018.

Gryphon Financial Partners reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2018 after selling out during the quarter.
Gryphon Financial Partners sold 217 Invesco Biotechnology & Genome ETF shares in Q3 2018, an estimated $12K.
Gryphon Financial Partners first reported a position in Invesco Biotechnology & Genome ETF in Q4 2017 and held it in 3 quarters.
Gryphon Financial Partners's Invesco Biotechnology & Genome ETF position peaked at $12K in Q2 2018.
74 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2018.

Based on Gryphon Financial Partners's 13F filing for Q3 2018, filed 6 Nov 2018.